Biogen Inc. will present data on Lecanemab, including 48-month results and a new subcutaneous formulation, at the Alzheimer’s Association International Conference. They will also explore tau-targeted therapies and biomarkers at the conference. The company is committed to advancing Alzheimer’s treatment and care.

BIIB080 is an investigational therapy targeting tau protein, currently being evaluated in a Phase 2 study for early Alzheimer’s disease. Biogen obtained the license for BIIB080 from Ionis Pharmaceuticals in 2019.

LEQEMBI (lecanemab) is approved for the treatment of Alzheimer’s disease and will be featured in presentations at the conference. Biogen and Eisai collaborate on the development and commercialization of AD treatments.

Read more at GlobeNewswire: Biogen to Highlight Scientific Progress Across Alzheimer’s